Following on from information provided to NICE by the company in January 2019, the appraisal of Paclitaxel as albumin-bound nanoparticles with gemcitabine for adjuvant treatment of pancreatic cancer [ID1413] was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued.
Status | Discontinued |
Technology type | Medicine |
Decision | Selected |
Process | TA |
ID number | 1413 |
Email enquiries
- If you have any queries please email scheduling@nice.org.uk
Timeline
Key events during the development of the guidance:
Date | Update |
---|---|
22 November 2022 | Discontinued. Following on from information provided to NICE by the company in January 2019, the appraisal of Paclitaxel as albumin-bound nanoparticles with gemcitabine for adjuvant treatment of pancreatic cancer [ID1413] was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued. |
09 March 2020 | The Department for Health and Social Care has asked NICE to carry out a Single Technology Appraisal of paclitaxel as albumin-bound nanoparticles with gemcitabine for adjuvant treatment of pancreatic cancer [ID1413]. For information, the company have advised that they are no longer pursuing a Marketing Authorisation Application from the European Medicines Agency for this indication at this time. Therefore, NICE has decided to suspend this appraisal from its current work programme. As this appraisal has been referred NICE will continue to monitor any development and will update interested parties if the situation changes. |
25 January 2019 | Suspended. The company has informed NICE that it will not provide an evidence submission for this appraisal. Therefore, we are suspending the appraisal while we consider the next steps |
22 July 2016 | In progress. Topic referred |
For further information on our processes and methods, please see our CHTE processes and methods manual